Mechanism Unveiled: Decoding GLP-1, GIP, and Glucagon Agonism The foundational mechanism underpinning current metabolic therapies involves the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are released from the gut in response to nutrient intake
Over time, evaporation through the needle tip can concentrate this small pocket, potentially causing a slight burning sensation during the initial portion of injection
However, these effects usually dissipate after a few weeks
The main limitation is the absence of long-term human data
These can compound the blood sugar-lowering effects of GLP-1 medications and increase the risk of dizziness, fainting, or severe hypoglycemia
[8] Both generics launched in May 2026 and target the Ozempic-equivalent doses (0.25 to 2 mg injectable)